On August 26, CANSINOBIO rose 14.34% in regular trading, trading at HK$32.78/share, with turnover of HK$55.90 million.

On the news front, the company announced on August 25 that its subsidiary CanSino Shanghai signed a strategic cooperation framework agreement with Depushi Bio for the co-development and commercialization of mRNA personalized therapeutic tumor vaccines. The partnership targets digestive tract solid tumors and rare tumor treatments on a global scale.

This collaboration follows a period of heightened market attention on mRNA oncology platforms after Moderna's INTerpath-001 Phase III trial achieved positive results for its personalized mRNA cancer vaccine. CANSINOBIO had surged approximately 48.59% on August 20 on that catalyst before pulling back over subsequent sessions. Institutional research from CLSA noted that CANSINOBIO's development route and antigen design are broadly similar to Moderna's, with a differentiated three-component lipid nanoparticle delivery system that may support stronger cellular immune responses. The new Depushi Bio partnership represents a concrete step in advancing the company's mRNA tumor vaccine pipeline from platform-level potential toward clinical development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)